The MONDO definition identifies loss of podocyte foot processes on electron microscopy, with unremarkable light microscopy, as the characteristic finding. No diagnostic methods, GeneReviews diagnosis content or newborn-screening information are supplied in this packet.

The packet's FDA records list cyclophosphamide (NDA, CDER; original approval date 1959-11-16; market status active). The packet does not state the indication for that record. No foundational-therapy or management content is supplied, so other treatments are unknown in this packet.

Prognosis is not certified in this packet; no natural history information is supplied.

ClinicalTrials.gov lists numerous registered studies for this condition. Examples in the packet include NCT07710157, a phase 2 obinutuzumab trial in adults with minimal change disease (Medical University Innsbruck; recruiting; 2026-07-13 to 2029-06-30); NCT06635720, a phase 3 reduced-dose steroid protocol study in childhood nephrotic syndrome (The Hospital for Sick Children; active, not recruiting; 2024-11-01 to 2027-02-28); NCT07861113, a phase 2 sibeprenlimab study in glomerular diseases including minimal change disease (Otsuka; not yet recruiting; start 2026-12-15); and NCT01209000, the Nephrotic Syndrome Study Network (University of Michigan; recruiting). Individuals interested in clinical trials can search ClinicalTrials.gov.